Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials

Diabetes - GeneralType 2 DiabetesGlycemic Control

Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials

Diabetes Obes Metab

Terauchi Y, Yabe D, Kaneto H, Amano A, Baxter M, Watanabe D, Watada H, Inagaki N

doi: 10.1111/dom.14139

Diabetes - GeneralType 2 DiabetesGlycemic Control

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

Diabetes Care.

Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group

Type 2 DiabetesGlycemic Control

Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia

Diabetes Obes Metab.

Aronson R, Umpierrez G, Stager W, Kovatchev B

doi: 10.1111/dom.13580.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials

Diabetes Technol Ther.

Sun D, Zhang X, Hou XX

doi: 10.1089/dia.2018.0132.

Type 2 Diabetes

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

Diabet Med.

Meneghini L, Doshi A, Gouet D, Vilsbøll T, Begtrup K, Őrsy P, Ranthe MF, Lingvay I

doi: 10.1111/dme.14178.

COMMENTED

Type 2 Diabetes

Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Diabetes Obes Metab.

Landgraf W, Owens DR, Frier BM, Zhang M, Bolli GB

doi: 10.1111/dom.13897.

Type 2 Diabetes

Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups

Diabetes Obes Metab.

Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H

doi: 10.1111/dom.

Type 2 Diabetes

Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial

Diabetes Obes Metab.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE

doi: 10.1111/dom.13844.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

JAMA.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P

doi: 10.1001/jama.2017.7117.

Related content

Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia

Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups

Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial